Turkovac Phase 3 trials to conclude soon: COVID-19 board member
“We want to keep all the schools open until the end of this year,” professor Ilhami Çelik, a member of Turkey’s Coronavirus Scientific Advisory Board, said in a statement on Sunday, emphasizing the country’s vaccination efforts and informing the public that the locally developed Turkovac vaccine will conclude its Phase 3 trials soon.
Speaking during an event in central Anatolian Kayseri province, Çelik said that emergency use approval will be granted to Turkovac depending on the results of its Phase 3 trials.
“This is an obligation during such times. You cannot wait 15 years for a vaccine during a pandemic,” he said.
“Therefore, safety is very important in Phases 1 and 2. First, the vaccines are given to a small group then to thousands of people, enabling us to see its adverse effects and recognize its safety. We are doing this quickly,” Çelik added.
Turkovac, previously known as ERUCOV-VAC before President Recep Tayyip Erdoğan renamed it, was developed in seven months by a team of scientists led by professor Aykut Özdarendeli. It started its Phase 1 trials in November 2020. Phase 2 trials began on Feb. 10, and as yet no side effects have been reported among volunteers.